Literature DB >> 8447527

High levels of interferon alpha in the sera of children with dengue virus infection.

I Kurane1, B L Innis, S Nimmannitya, A Nisalak, A Meager, F A Ennis.   

Abstract

We measured the levels of interferon alpha (IFN alpha) in the sera of Thai children hospitalized with dengue hemorrhagic fever (DHF) or dengue fever (DF) to examine the role of IFN alpha in dengue virus infections of humans. The percentage of patients who had detectable levels of IFN alpha (> or = 3 U/ml) was higher in patients with DHF (80%, P < 0.001) and in patients with DF (60%, P < 0.001) than in healthy Thai children (7%). The levels of IFN alpha were higher in patients with DHF and in patients with DF on the first few days after the onset of fever than in healthy Thai children. The average levels of IFN alpha in patients with DHF were high two days before defervescence, decreasing gradually until the day of defervescence. There was a subset of patients with DHF who had increasing levels of IFN alpha after defervescence. However, the levels of IFN alpha in patients with DF were not high after fever subsided. The levels of IFN alpha were not different among children with DHF grades 1, 2 and 3. Among patients with DHF, T lymphocytes were activated to a higher degree in high IFN alpha producers than in low IFN alpha producers. These results indicate that similarly high levels of IFN alpha are produced in vivo during the acute stages of DHF and DF, and that high levels of IFN alpha remain after fever subsides in some patients with DHF, but not in patients with DF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447527     DOI: 10.4269/ajtmh.1993.48.222

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  47 in total

1.  Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation.

Authors:  M Juffrie; G M van Der Meer; C E Hack; K Haasnoot; A J Veerman; L G Thijs
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses.

Authors:  Jorge L Muñoz-Jordán; Maudry Laurent-Rolle; Joseph Ashour; Luis Martínez-Sobrido; Mundrigi Ashok; W Ian Lipkin; Adolfo García-Sastre
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis.

Authors:  Karen Clyde; Jennifer L Kyle; Eva Harris
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

4.  Interferonemia and autism.

Authors:  G Stubbs
Journal:  J Autism Dev Disord       Date:  1995-02

5.  Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

Authors:  M S Diamond; T G Roberts; D Edgil; B Lu; J Ernst; E Harris
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide.

Authors:  Yun-Chi Chen; Sheng-Yuan Wang
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  An IRF-3-, IRF-5-, and IRF-7-Independent Pathway of Dengue Viral Resistance Utilizes IRF-1 to Stimulate Type I and II Interferon Responses.

Authors:  Aaron F Carlin; Emily M Plummer; Edward A Vizcarra; Nicholas Sheets; Yunichel Joo; William Tang; Jeremy Day; Jay Greenbaum; Christopher K Glass; Michael S Diamond; Sujan Shresta
Journal:  Cell Rep       Date:  2017-11-07       Impact factor: 9.423

8.  Cardif-mediated signaling controls the initial innate response to dengue virus in vivo.

Authors:  Stuart T Perry; Tyler R Prestwood; Steven M Lada; Chris A Benedict; Sujan Shresta
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

9.  New mouse model for dengue virus vaccine testing.

Authors:  A J Johnson; J T Roehrig
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  TRAIL is a novel antiviral protein against dengue virus.

Authors:  Rajas V Warke; Katherine J Martin; Kris Giaya; Sunil K Shaw; Alan L Rothman; Irene Bosch
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.